Stock Events

Stock Events

Inhibitor Therapeutics 

$0.078550
8
+$0.02+33.14% 14:16 Today

Statistics

Day High
0.1
Day Low
0.1
52W High
0.124
52W Low
0.04
Volume
1,000
Avg. Volume
6,446
Mkt Cap
13.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Nov 15Expected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
0
Expected EPS
0
Actual EPS
-0.0003

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INTI. It's not an investment recommendation.
ProShares Bitcoin
3
BITO
Schwab US Dividend Equity
2
SCHD
YieldMax Ultra Option Income Strategy
2
ULTY
International Business Machines
2
IBM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is a biopharmaceutical company that competes in the development of antiviral drugs, directly competing with Inhibitor Therapeutics' focus on therapeutic solutions.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie operates in the same biopharmaceutical space, focusing on innovative therapies, including inhibitors for various diseases, making it a direct competitor.
AMGEN
AMGN
Mkt Cap217.9B
Amgen focuses on human therapeutics, including the development of inhibitory drugs for cancer and other diseases, competing in the same therapeutic area as Inhibitor Therapeutics.
Merck
MRK
Mkt Cap356.01B
Merck is known for its contributions to healthcare, including the development of drugs that inhibit the progression of diseases, positioning it as a competitor.
Pfizer
PFE
Mkt Cap158.45B
Pfizer develops and manufactures healthcare products, including inhibitors for various conditions, making it a competitor in the pharmaceutical and biotech industry.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb is involved in the discovery, development, and delivery of medicines, including inhibitors, competing in the same therapeutic areas as Inhibitor Therapeutics.
Novartis
NVS
Mkt Cap268B
Novartis focuses on innovative medicines, including inhibitors for chronic diseases, directly competing with Inhibitor Therapeutics in the pharmaceutical sector.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in the pharmaceutical and diagnostics space, focusing on innovative drugs including inhibitors, making it a competitor in the healthcare market.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson is a diverse healthcare company that develops pharmaceuticals, including inhibitory drugs, competing across multiple healthcare sectors.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals specializes in the invention of medicines for serious medical conditions, including inhibitors, directly competing in the biopharmaceutical field.

About

Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Show More
CEO
Francis E. O'Donnell Jr.
Employees
8
Country
United States
ISIN
US45720M1053

Listings

OTC Link
US
INTI

0 Comments

Share your thoughts

FAQs

What is Inhibitor Therapeutics stock price today?▼
The current price of INTI is $0.08 USD — it has increased by +33.14% in the past 24 hours. Watch Inhibitor Therapeutics stock price performance more closely on the chart.
What is Inhibitor Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Inhibitor Therapeutics stocks are traded under the ticker INTI.
Is Inhibitor Therapeutics stock price growing?▼
INTI stock has fallen by -39.8% compared to the previous week, the month change is a -41% fall, over the last year Inhibitor Therapeutics has showed a +22.92% increase.
What is Inhibitor Therapeutics market cap?▼
Today Inhibitor Therapeutics has the market capitalization of 13.65M
What were Inhibitor Therapeutics earnings last quarter?▼
INTI earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inhibitor Therapeutics revenue for the last year?▼
Inhibitor Therapeutics revenue for the last year amounts to 0 USD.
What is Inhibitor Therapeutics net income for the last year?▼
INTI net income for the last year is -3.3M USD.
How many employees does Inhibitor Therapeutics have?▼
As of October 13, 2026, the company has 8 employees.
In which sector is Inhibitor Therapeutics located?▼
Inhibitor Therapeutics operates in the Health & Wellness sector.
When did Inhibitor Therapeutics complete a stock split?▼
Inhibitor Therapeutics has not had any recent stock splits.
Where is Inhibitor Therapeutics headquartered?▼
Inhibitor Therapeutics is headquartered in Tampa, United States.